RBC Capital Upgrades IGM Biosciences to Outperform, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams upgraded IGM Biosciences (NASDAQ:IGMS) from Sector Perform to Outperform and increased the price target from $9 to $21.
February 09, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IGM Biosciences was upgraded by RBC Capital from Sector Perform to Outperform with a price target increase from $9 to $21.
Upgrades by reputable analysts like RBC Capital typically lead to positive short-term price movements. The substantial increase in the price target from $9 to $21 indicates a strong conviction in the company's future performance, likely influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100